Global Ganja Report

Cannabis is set to become legal in Michigan after voters in the Wolverine State passed Proposal 1 during the midterm elections. 

The passage of Prop 1 makes Michigan the 10th state in the nation and the first in the Midwest to legalize cannabis for "recreational" use, joining California, Oregon, Washington, Alaska, Colorado, Nevada, Massachusetts, Vermont, Maine and Washington DC.

Voters in several states will cast ballots on cannabis-related measures in the Nov. 6 midterm election. Michigan and North Dakota are facing general legalization measures, while Utah and Missouri voters will get to weigh in on medical marijuana.

A major player in Canada's legal cannabis sector is seeking to acquire a troubled US-based company—the latest example of the trend toward consolidation in the industry now crossing international borders.

After years of upholding employee firings for use of cannabis even under state medical marijuana programs, the courts are finally starting to turn around on the question.

One of the ways state medical marijuana programs have failed to fully extend protection to medicinal users is in failure to defend against employment discrimination. This is now beginning to change, thanks to a few recent court decisions in favor of patients and employees.

Last month, the DEA enthused the pharmaceutical industry but disappointed cannabis advocates by re-scheduling the drug Epidiolex—but not CBD, the cannabinoid that makes it work. Now word emerges of a letter to the DEA by the Food & Drug Administration essentially calling for the descheduling of CBD altogether.

Among several cannabis-related bills signed into law by California's Gov. Jerry Brown was one creating an "equity" program for the state's legalized industry, aimed at justice and inclusion for those communities hardest hit by marijuana prohibition. Another measure will erase past convictions for possession of cannabis in quantities that are now legal.

With the DEA's rescheduling of Epidiolex, shares in the British manufacturer of the drug are soaring. But CBD—the actual cannabinoid that the product is based on—is to remain in the restrictive Scheudle 1.

As the UN General Assembly met in New York, President Trump issued a "Global Call" to renew the war on drugs—to the dismay of activists and dissenting nations. But the UN itself has a contradictory cannabis policy—with some agencies recognizing its efficacy as medicine and others backing the prohibitionist doctrine of the Single Convention treaty.